Paul Eckerle, MD
Pulmonary Disease · Belleville, ILNPI 1215317409
Payments from drug & device makers
Across 296 payments — averaging $61.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Sanofi$6K
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$512
- Regeneron Healthcare Solutions, Inc.$476
- plus $1K from 17 others
What the payments were for
- Consulting fees$4,58525%
- Travel & lodging$2,09711%
- Food & beverage$7,63042%
- Education$4,01022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $6,333 |
| Sanofi | 38 | $6,050 |
| AstraZeneca | 75 | $2,005 |
| GSK | 58 | $1,550 |
| Boehringer Ingelheim | 23 | $512 |
| Regeneron Healthcare Solutions, Inc. | 23 | $476 |
| Grifols USA, LLC | 10 | $325 |
| Electromed, Inc. | 28 | $253 |
| Genentech USA, Inc. | 1 | $130 |
| Mylan Specialty L.p. | 7 | $126 |
| Merck | 1 | $123 |
| Philips North America LLC | 6 | $117 |
| La Jolla Pharmaceutical Company | 1 | $79 |
| Baxter Healthcare | 2 | $51 |
| Boston Scientific | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Optinose US, Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Insmed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,123
- DUPIXENT$5,474
- NUCALA$596
- TEZSPIRE$491
- Prolastin-C Liquid$162
- WINREVAIR$123
How this compares
$18,323 in reported general payments places this provider in the 80th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 776 | $572,732 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 304 | $224,549 |
| OfevNintedanib Esylate | 21 | $204,119 |
| Dupixent PenDupilumab | 29 | $125,154 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 240 | $120,990 |
| Breo ElliptaFluticasone/Vilanterol | 142 | $65,704 |
| Spiriva RespimatTiotropium Bromide | 82 | $51,468 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 82 | $47,352 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 37 | $17,492 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $16,689 |
| EliquisApixaban | 20 | $12,188 |
| Roflumilast | 101 | $11,039 |
| Spiriva HandihalerTiotropium Bromide | 14 | $10,022 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 387 | $9,386 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 54 | $9,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,550 | $766,3691,174 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $512 | $302,939185 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $2,005 | $258,729401 claims |
| MerckDulera | $123 | $4,41914 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $18 | $1,61424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Belleville
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Shashi BellamEvanston$1.2M
- Marilyn GlassbergMaywood$1000K
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
- Patrick WhittenPeoria$812K
- Jane Dematte DamicoChicago$811K
- Septimiu MurguChicago$804K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.